Diabetic microvascular complications: Possible targets for improved macrovascular outcomes

International Journal of Nephrology and Renovascular Disease

Volumn 4, Issue , 2011, Pages 1-15

  D'Elia, John A ^a   Bayliss, George ^a,b   Roshan, Bijan ^a   Maski, Manish ^a   Gleason, Ray E ^a   Weinrauch, Larry A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

Angiotensin converting enzyme inhibitor; Beta cells; Cardiac autonomic neuropathy; Diabetic nephropathy; Podocytes; Pulsatile insulin

Indexed keywords

ANGIOTENSIN II; ATENOLOL; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG METABOLITE; ENALAPRIL; EPLERENONE; EXP 3179; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; INSULIN; IRBESARTAN; LISINOPRIL; LOSARTAN; METFORMIN; PLACEBO; QUINAPRIL; SPIRONOLACTONE; TRANDOLAPRIL; UNCLASSIFIED DRUG;

ALBUMINURIA; BLOOD PRESSURE REGULATION; CARDIOVASCULAR SYSTEM EXAMINATION; CREATININE CLEARANCE; DIABETES CONTROL; DIABETIC ANGIOPATHY; DIABETIC CARDIOMYOPATHY; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DOSAGE SCHEDULE COMPARISON; DRUG PULSE THERAPY; EYE EXAMINATION; GLYCEMIC CONTROL; HEART HEMODYNAMICS; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY BLOOD FLOW; KIDNEY EXAMINATION; KIDNEY FAILURE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PODOCYTE; PROSTAGLANDIN BLOOD LEVEL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT; THROMBOCYTE AGGREGATION; TISSUE INJURY;

EID: 79952948374     PISSN: None     EISSN: 11787058     Source Type: Journal    
DOI: 10.2147/IJNRD.S14716     Document Type: Review

References (118)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-986.
2. Lewis E, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensinconverting- enzyme inhibition on diabetic nephropathy. N Engl J Med.1993;329(20):1456-1462.
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-853.
4. UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317(7160):703-713.
5. Gerstein HC, Miller ME, et al; ACCORD Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358(24):2545-2559.
6. Cushman WC, Evans GW, et al; ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575-1585.
7. Wolf G, Ziyadeh FN, Helmchen U, Zahner G, Schroeder R, Stahl RA. ANG II is a mitogen for a murine cell line isolated from medullary thick ascending limb of Henle's loop. Am J Physiol. 1995;268 (5 Pt 2):F940-F947.
8. Ziyadeh FN, Sharma K, Ericksen M, Wolf G. Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-beta. J Clin Invest. 1994;93(2):536-542.
9. Mauer M, Zinman B, Gardiner R, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med. 2009;361(1): 40-51.
10. Persson F, Rossing P, Hovind P, et al. Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudy. Diabetes. 2006;55(12): 3550-3555.
11. Furumatsu Y, Nagasawa Y, Tomida K, et al. Effect of renin-angiotensinaldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker. Hypertens Res. 2008;31(1):59-67.
12. Mehdi UF, Adams-Huet B, Raskin P, Vega GL, Toto RD. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol. 2009;20(12):2641-2650.
13. D'Elia JA, Weinrauch LA, Gleason RE, Lipinska I, Pendse S, Roshan B, Lee AT, Tofler G. Fibrinogen and factor VII levels improve with glycemic control in patients with type 1 diabetes mellitus who have microvascular complications. Arch Intern Med. 2001; 161(1):98-101.
14. Aoki TT, Benbarka MM, Okimura MC, et al. Long-term intermittent intravenous insulin therapy and type 1 diabetes mellitus. Lancet. 1993; 342(8870):515-518.
15. Aoki TT, Grecu EO, Arcangeli MA. Chronic intermittent intravenous insulin therapy corrects orthostatic hypotension of diabetes. Am J Med.1995;99(6):683-684.
16. Aoki TT, Grecu EO, Prendergast JJ, Arcangeli MA, Meisenheimer R. Effect of chronic intermittent intravenous insulin therapy on antihypertensive medication requirements in IDDM subjects with hypertension and nephropathy. Diabetes Care. 1995;18(9):1260-1265.
17. Dailey GE, Boden GH, Creech RH, Johnson D, Gleason RE, Kennedy FP, Weinrauch LA, Weir M, D'Elia J. Effects of pulsatile intravenous insulin therapy on the progression of diabetic nephropathy. Metabolism.2000;49(11):1491-1495.
18. Weinrauch LA, Burger AJ, Aepfelbacher F, Lee AT, Gleason RE, D'Elia JA. A pilot study to test the effect of pulsatile insulin infusion on cardiovascular mechanisms that might contribute to attenuation of renal compromise in type 1 diabetes mellitus patients with proteinuria. Metabolism. 2007;56(11):1453-1457.
19. Weinrauch LA, Gleason RE, D'Elia JA. What have trials of pulsatile intravenous insulin taught us? Metabolism. 2010;59(5): 764-765.
20. Niswender K. Early and aggressive initiation of insulin therapy for type 2 diabetes: what is the evidence? Clin Diabetes. 2009;27(2):60-68.
21. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med.2008;359(15):1577-1589.
22. Aepfelbacher FC, Yeon SB, Weinrauch LA, D'Elia J, Burger AJ. Improved glycemic control induces regression of left ventricular mass in patients with type 1 diabetes mellitus. Int J Cardiol. 2004;94(1): 47-51.
23. Spiro MJ, Kumar BR, Crowley TJ. Myocardial glycoproteins in diabetes: type VI collagen is a major PAS-reactive extracellular matrix protein. J Moll Cell Cardiol. 1992;24(4):397-410.
24. D'Elia JA, Weinrauch LA, Healy RW, Libertino JA, Bradley RF, Leland OS Jr. Myocardial dysfunction without coronary artery disease in diabetic renal failure. Am J Cardiol. 1979;43(2):193-199.
25. Burger AJ, Weinrauch LA, D'Elia JA, Aronson D. Effect of glycemic control on heart rate variability in type I diabetic patients with cardiac autonomic neuropathy. Am J Cardiol. 1999;84(6):687-691.
26. Weinrauch LA, Burger A, Gleason RE, Lee AT, D'Elia JA. Left ventricular mass reduction in type 1 diabetic patients with nephropathy. J Clin Hypertens (Greenwich). 2005;7(3):159-164.
27. Weinrauch LA, Bayliss G, Gleason RE, Lee AT, D'Elia JA. Utilization of an abbreviated diabetes impact management scale to assess change in subjective disability during a trial of pulsatile insulin delivery demonstrates benefit. Metabolism. 2009;58(4):488-491.
28. Duran-Jimenez B, Dobler D, Moffatt S, et al. Advanced glycation end products in extracellular matrix proteins contribute to the failure of sensory nerve regeneration in diabetes. Diabetes. 2009;58(12): 2893-2903.
29. Quattrini C, Tavakoli M, Jeziorska M, et al. Surrogate markers of small fiber damage in human diabetic neuropathy. Diabetes. 2007;56(8): 2148-2154.
30. Mehra S, Tavakoli M, Kallinikos PA, et al. Corneal confocal microscopy detects early nerve regeneration after pancreas transplantation in patients with type 1 diabetes. Diabetes Care. 2007;30(10):2608-2612.
31. Chaturvedi N, Porta M, Klein R, et al. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (Direct-Protect 1) of retinopathy in type 1 diabetes: randomized, placebo-controlled trials. Lancet. 2008;372(9647):1394-1402.
32. Chaturvedi N, Sjolie AK, Stephenson JM, et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID study group. EURODIAB controlled trial of lisinopril in insulin dependant diabetes mellitus. Lancet. 1998;351(9095):28-31.
33. Sjolie A, Klein R, Porta M, et al. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomized placebo-controlled trial. Lancet. 2008;372(9647): 1385-1393.
34. Beulens JW, Patel A, Vingerling JR, et al. Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial. Diabetologia. 2009;52(10):2027-2036.
35. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet. 1998;351(9118):1755-1762.
36. Devaraj S, Cheung AT, Jialal I, et al. Evidence of increased inflammation and microcirculatory abnormalities in patients with type 1 diabetes and their role in microvascular complications. Diabetes.2007;56(11):2790-2796.
37. Gardner TW, Sander B, Larsen ML, et al. An extension of the Early Treatment Diabetic Retinopathy Study (ETDRS) system for grading of diabetic macular edema in the astemizole retinopathy trial. Curr Eye Res. 2006;31(6):535-547.
38. Silva KC, Rosales MAB, Biswas SK, Lopes de Faria JB, Lopes de Faria JM. Diabetic retinal neurodegeneration is associated with mitochondrial oxidative stress and is improved by an angiotensin receptor blocker in a model combining hypertension and diabetes. Diabetes.2009;58(6):1382-1390.
39. Early Treatment Diabetic Retinopathy Study Group. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Opthalmology. 1991;98 Suppl 5:823-833.
40. Weinrauch LA, Sun J, Gleason RE, Boden GH, Creech RH, Dailey G, Kennedy FP, Weir MR, D'Elia JA. Pulsatile intermittent intravenous insulin therapy for attenuation of retinopathy and nephropathy in type 1 diabetes mellitus. Metabolism. 2010;59(10): 1429-1434.
41. Weinrauch LA, Sun J, Gleason RE, Boden GH, Creech RH, Dailey G, Kennedy FP, Weir MR, D'Elia JA. Progression of retinopathy in type 1 diabetic patients with nephropathy: impact of glycemia control as measured by variation in glycohemoglobin A1C. J Am Soc Nephrol.2009;20: Abstract.
42. Waden J, Forsblom C, Thorn LM, Gordin D, Saraheimo M, Groop P-H. A1C variability predicts incident cardiovascular events, microalbuminuria, and overt diabetic nephropathy in patients with type 1 diabetes. Diabetes. 2009;58(11):2649-2655.
43. Kilpatrick ES, Rigby AS, Atkin SL. A1C variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial. Diabetes Care. 2008;31(11): 2198-2202.
44. Flammer AJ, Hermann F, Wiesli P, et al. Effect of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension. J Hypertens.2007;25(4):785-791.
45. Kramer C, Sunkomat J, Witte J, et al. Angiotensin II receptorindependent anti-inflammatory and antiaggregatory properties of losartan: role of active metabolite EXP3179. Circ Res. 2002;90(7): 770-776.
46. Fortuno A, Bidegain J, Robador P, et al. Losartan metabolite EXP3179 blocks NADPH oxidase-mediated superoxide production by inhibiting protein kinase C: potential clinical implications in hypertension. Hypertension. 2009;54(4):744-750.
47. Qudit GY, Liu GC, Zhong J, et al. Human recombinant ACE2 reduces the progression of diabetic nephropathy. Diabetes. 2010;59(2):529-538.
48. Sharma HS, van Heugten HA, Goedbloed MA, Verdouw PD, Lamers JM. Angiotensin II induced expression of transcription factors precedes increase in transforming growth factor-beta 1 mRNA in neonatal cardiac fibroblasts. Biochem Biophys Res Commun. 1994;205(1):105-112.
49. Ma LJ, Nakamura S, Aldigier JC, et al. Regression of glomerulosclerosis with high-dose angiotensin inhibition is linked to decreased plasminogen activator inhibitor-1. J Am Soc Nephrol. 2005;16(4):966-976.
50. Onozato ML, Tojo A, Kobayashi N, Goto A, Matsuoka H, Fujita T. Dual blockade of aldosterone and angiotensin II additively suppresses TGF-beta and NADPH oxidase in the hypertensive kidney. Nephrol Dial Transplant. 2007;22(5):1314-1322.
51. Nemeth Z, Kokeny G, Godo M, et al. Increased renoprotection with ACE inhibitor plus aldosterone antagonist as compared to montherapies- the effect on podocytes. Nephrol Dial Transplant. 2009;24(12): 3640-3651.
52. Agarwal R. Vitamin D, proteinuria, diabetic nephropathy, and progression of CKD. Clin J Am Soc Nephrol. 2009;4(9):1523-1528.
53. Zhang Y, Kong J, Deb DK, Chang A, Li YC. Vitamin D receptor attenuates renal fibrosis by suppressing the renin-angiotensin system. J Am Soc Nephrol. 2010;21(6):966-973.
54. Mizobuchi M, Nakamura H, Tokumoto M, et al. Myocardial effects of VDR activators in renal failure. J Steroid Biochem Mol Biol. 2010; 121(1-2):188-192.
55. Avendano GF, Agarwal RK, Bashey RI, et al. Effects of glucose intolerance on myocardial function and collagen-linked glycation. Diabetes.1999;48(7):1443-1447.
56. Gruden G, Thomas S, Burt D, et al. Mechanical stretch induces vascular permeability factor in human mesangial cells: mechanisms of signal transduction. Proc Natl Acad Sci U S A. 1997;94(22): 12112-12116.
57. Kim HW, Kim JL, Lee HK, Hur DY, Yun IH, Kim SD. Enalapril alters expression of key growth factors in experimental diabetic retinopathy. Curr Eye Res. 2009;34(11):976-987.
58. Zheng Z, Chen H, Xu X, Li C, Gu Q. Effects of angiotensin-converting enzyme inhibitors and beta adrenergic blockers on retinal vascular endothelial growth factor expression in rat diabetic retinopathy. Exp Eye Res. 2007;84(4):745-752.
59. Fukumoto M, Takai S, Ishizaki E, et al. Involvement of angiotensin II-dependent vascular endothelial growth factor gene expression via NADPH oxidase in the retina in a type 2 diabetic rat model. Curr Eye Res. 2008;33(10):885-891.
60. Kim JH, Kim JH, Yu YS, Cho CS, Kim KW. Blockade of angiotensin II attenuates VEGF-medicated blood-retinal barrier breakdown in diabetic retinopathy. J Cereb Blood Flow Metab. 2009;29(3):621-628.
61. Wilkinson-Berka JL, Tan G, Jaworski K, Miller AG. Identification of a retinal aldosterone system and the protective effects of mineralocorticoid receptor antagonism on retinal vascular pathology. Circ Res.2009;104(1):124-133.
62. Leopold JA, Dam A, Maron BA, et al. Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med. 2007;13(2):189-197.
63. Watanabe T, Suzuki J, Yamawaki H, Sharma VK, Sheu SS, Berk BC. Losartan metabolite EXP3179 activates Akt and endothelial nitric oxide synthase via vascular endothelial growth factor receptor-2 in endothelial cells: angiotensin II type 1 receptor-independent effects of EXP3179. Circulation. 2005;112(12):1798-1805.
64. Michel F, Ambroisine ML, Duriez M, Delcayre C, Levy B, Silvestre JS. Aldosterone enhances ischemia-induced neovascularization through angiotensin II-dependent pathway. Circulation. 2004; 109(16): 1933-1937.
65. Parving HH, Brenner BM, McMurray JJ, et al. Aliskiren trial in type 2 diabetes using cardio-renal endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant. 2009;24(5):1663-1671.
66. Lacy PE, Howell SL, Young DA, Fink CJ. New hypothesis of insulin secretion. Nature. 1968;219(5159):1177-1179.
67. Orci L, Gabbay K, Malaisse WJ. Pancreatic beta-cell web: it's possible role in insulin secretion. Science. 1972;175(26):1128-1130.
68. Verma R, Kovari I, Soofi A, Nihalani D, Patrie K, Holzman LB. Nephrin ectodomain engagement results in SRC kinase activation, nephrin phosphorylation, NCK recruitment, and actin polymerization. J Clin Invest. 2006;116(5):1346-1359.
69. Coward RJ, Welsh GI, Koziell A, et al. Nephrin is critical for the action of insulin on human glomerular podocytes. Diabetes. 2007;56(4): 1127-1135.
70. Fornoni A, Jeon J, Varona Santos J, et al. Nephrin is expressed on the surface of insulin vesicles and facilitates glucose-stimulated insulin release. Diabetes. 2010;59(1):190-199.
71. Jewell JL, Luo W, Oh E, Wang Z, Thurmond DC. Filamentous actin regulates insulin exocytosis through direct interaction with syntaxin 4. J Biol Chem. 2008;283(16):10716-10726.
72. Wendt T, Tanji N, Guo J, et al. Glucose, glycation, and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathy. J Am Soc Nephrol. 2003;14(5):1383-1395.
73. Chuang PY, Yu Q, Fang W, Uribarri J, He JC. Advanced glycation endproducts induce podocyte apoptosis by activation of the FOXO4 transcription factor. Kidney Int. 2007;72(8):965-976.
74. Saleem S, Zavadil J, Bailly M, et al. The molecular and functional phenotype of glomerular podocytes reveals key features of contractile smooth muscle cells. Am J Physiol Renal Physiol. 2008;295(4): F959-F970.
75. Saitoh Y, Hongwei W, Ueno H, Mizuta M, Nakazato M. Telmisartan attenuates fatty-acid-induced oxidative stress and NAD(P)H oxidase activity in pancreatic beta-cells. Diabetes Metab. 2009;35(5):392-397.
76. Chu KY, Cheng Q, Chen C, et al. Angiotensin exerts glucose-dependent effects on Kv current in mouse pancreatic beta-cells via angiotensin II type 2 receptors. Am J Physiol. 2010;298(2):C313-C323.
77. Marchetti P, Del Guerra S, Marselli L, et al. Pancreatic islets from type 2 diabetic patients have functional defects and increased apoptosis that are ameliorated by metformin. J Clin Endocrinol Metab. 2004;89(11):5535-5541.
78. Sasaki H, Asanuma H, Fujita M, et al. Metformin prevents progression of heart failure in dogs: role of AMP-activated protein kinase. Circulation.2009;119(19):2568-2577.
79. Hussain S, Romio L, Saleem M, et al. Nephrin deficiency activates NFkappaB and promotes glomerular injury. J Am Soc Nephrol. 2009;20(8): 1733-1743.
80. Sheerin NS. A novel role for nephrin in the maintenance of glomerular structure. J Am Soc Nephrol. 2009;20(8):1661-1663.
81. Sharma K, Ramachandra Rao S, Qui G, et al. Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest. 2008; 118(5):1645-1656.
82. Ouchi N, Kihara S, Arita Y, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation. 2000;102(11):1296-1301.
83. S, Bonet J, Lopez D, Casas I, Romero R. ACE inhibitors improve nephrin expression in Zucker rats with glomerulosclerosis. Kidney Int Suppl. 2005;(93):S10-S14.
84. Michael D, Xiong W, Geng X, Drain P, Chow RH. Human insulin vesicle dynamics during pulsatile secretion. Diabetes. 2007;56(5): 1277-1288.
85. Porksen N, Munn S, Steers J, Veldhuis J, Butler PC. Effects of glucose ingestion versus infusion on pulsatile insulin secretion: the incretin effect is achieved by amplification of insulin secretory burst mass. Diabetes. 1996;45(10):1317-1323.
86. Juhl CB, Porksen N, Pincus SM, Hansen AP, Veldhuis JD, Schmitz O. Acute and short-term administration of a sulfonylurea (gliclazide) increases pulsatile insulin secretion in type 2 diabetes. Diabetes.2001;50(8):1778-1784.
87. Ritzel R, Schulte M, Porksen N, et al. Glucagon-like peptide 1 increases secretory burst mass of pulsatile insulin secretion in patients with type 2 diabetes and impaired glucose tolerance. Diabetes. 2001; 50(4):776-784.
88. Matthews DR, Lang DA, Burnett MA, Turner RC. Control of pulsatile insulin secretion in man. Diabetologia. 1983;24(4):231-237.
89. Rosengren AH, Jokubka R, Tojjar D, et al. Overexpression of alpha 2 A-adrenergic receptors contributes to type 2 diabetes. Science. 2010; 327(5962):217-220.
90. Gribble FM. Alpha 2 A-adrenergic receptors and type 2 diabetes. N Engl J Med. 2010;362(4):361-362.
91. Weigle DS, Koerker DJ, Goodner CJ. Pulsatile glucagon delivery enhances glucose production by perifused rat hepatocytes. Am J Physiol. 1984;247(4 Pt 1):E564-E568.
92. Lang DA, Matthews DR, Petro J, Turner RC. Cyclic oscillations of basal plasma glucose and insulin concentrations in human beings. N Engl J Med. 1979;301(19):1023-1027.
93. Jaspan JB, Lever E, Polonsky KS, van Cauter E. In vivo pulsatility of pancreatic islet peptides. Am J Physiol. 1986;251(2 Pt 1): E215-E226.
94. Lau T, Carlsson PO, Leung PS. Evidence for a local angiotensingenerating system and dose-dependent inhibition of glucosestimulated insulin release by angiotensin II in isolated pancreatic islets. Diabetologia.2004;47(2):240-248.
95. Fliser D, Schaefer F, Schmid D, Veldhuis JD, Ritz E. Angiotensin II affects basal, pulsatile and glucose-stimulated insulin secretion in humans. Hypertension. 1997;30(5):1156-1161.
96. Bernanke D, Epstein FH. Metabolism of the renal medulla. Am J Physiol. 1965;208:541-545.
97. Lee JB, Vance VK, Cahill GF Jr. Metabolism of C14-labeled substrates by rabbit kidney cortex and medulla. Am J Physiol. 1962;203:27-36.
98. Martinez-Maldonado M, Allen JC, Eknoyan G, Suki W, Schwartz A. Renal concentrating mechanism: possible role for sodium-potassium activated adenosine triphosphatase. Science. 1969;165(895):807-808.
99. Leichtweiss H, Lubbers D, Weiss C, Baumgartl H, Resche W. The oxygen supply of the rat kidney: measurements of intrarenal pO2. Pfluegers Arch. 1969;309:328-349.
100. Aukland K, Krog J. Renal oxygen tension. Nature. 1960;188:671.
101. Lilienfield LS, Rose JC, Lassen NA. Diverse distribution of red cells and albumin in the dog kidney. Circ Res. 1958;6(6):810-815.
102. Aoki TT, Vlachokosta FV, Foss MC, Meistas MT. Evidence for restoration of hepatic glucose processing in type I diabetes mellitus. J Clin Invest. 1983;71(4):837-839.
103. Jacobsson LT, Turesson C, Gulfe A, et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol.2005;32(7):1213-1218.
104. Porter KE, Turner NA. Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol Ther. 2009;123(2):255-278.
105. Sekiguchi K, Li X, Coker M, et al. Cross-regulation between the reninangiotensin system and inflammatory mediators in cardiac hypertrophy and failure. Cadiovasc Res. 2004;63(3):433-442.
106. Hwang MW, Matsumori A, Furukawa Y, et al. Neutralization of interleukin-1beta in the acute phase of myocardial infarction promotes the progression of left ventricular remodeling. J Am Coll Cardiol.2001;38(5):1546-1553.
107. Flesch M, Höper A, Dell'Italia L, et al. Activation and functional significance of the renin-angiotensin system in mice with cardiac restricted overexpression of tumor necrosis factor. Circulation. 2003;108(5):598-604.
108. Nakamura K, Kusano K, Nakamura Y, et al. Carvedilol decreases elevated oxidative stress in human failing myocardium. Circulation.2002;105(24):2867-2871.
109. Mochizuki M, Yano M, Oda T, et al. Scavenging free radicals by low-dose carvedilol prevents redox-dependent Ca2+ leak via stabilization of ryanodine receptor in heart failure. J Am Coll Cardiol.2007;49(16):1722-1732.
110. Delbosc S, Cristol JP, Descomps B, Mimran A, Jover B. Simvastatin prevents angiotensin II-induced cardiac alteration and oxidative stress. Hypertension. 2002;40(2):142-147.
111. Moe GW, Marin-Garcia J, Konig A, Goldenthal M, Lu X, Feng Q. In vivo TNF-alpha inhibition ameliorates cardiac mitochondrial dysfunction, oxidative stress, and apoptosis in experimental heart failure. Am J Physiol Heart Circ Physiol. 2004;287(4):H1813-H1820.
112. Li S, Jiao X, Tao L, et al. Tumor necrosis factor-alpha in mechanic trauma plasma mediates cardiomyocyte apoptosis. Am J Physiol Heart Circ Physiol. 2007;293:H1847-H1852.
113. Valgimigli M, Merli E, Malagutti P, et al. Hydroxyl radical generation, levels of tumor necrosis factor-alpha, and progression to heart failure after acute myocardial infarction. J Am Coll Cardiol. 2004; 43(11):2000-2008.
114. Lerolle N, Bourgeois S, Leviel F, Lebrun G, Paillard M, Houillier P. Angiotensin II inhibits NaCl absorption in the rat medullary thick ascending limb. Am J Physiol Renal Physiol. 2004;287(3):F404-F410.
115. Shahid M, Francis J, Majid DS. Tumor necrosis factor-alpha induces renal vasoconstriction as well as natriuresis in mice. Am J Physiol Renal Physiol. 2008;295(6):F1836-F1844.
116. Ogawa S, Mori T, Nako K, Kato T, Takeuchi K, Ito S. Angiotensin II type 1 receptor blockers reduce oxidative stress markers in hypertensive diabetic nephropathy. Hypertension. 2006;47(4):699-705.
117. Stokes MB, Foster K, Markowitz GS, et al. Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis. Nephrol Dial Transplant. 2005;20(7):1400-1406.
118. Hirsch IB, Brownlee M. Beyond hemoglobin A1c-need for additional markers of risk for diabetic microvascular complications. JAMA.2010;303(22):2291-2292.